FDA
-
-
-
-
-
-
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
-
-
-
-
-
-
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
-
-
-
-
-
-
-
Lyell Immunopharma (LYEL) Receives RMAT Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
-
-
-
-
-
-
-
Lyell Immunopharma (LYEL) to Acquire ImmPACT Bio, Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
-
-
-
-
-
-
-
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
-
-
-
-
-
-
-
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
-
-
-
-
-
-
-
Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

